than current protocols. Recent scientific research and therapeutic advancesCollaboration between university researchers and physicians has led to a proliferation of studies on the anticancer effects of cannabinoids. Several laboratories are currently exploringexperimental treatments for various oncological indications, particularly forovarian cancer. It is important to remember, however, that the majority of this data still comes from laboratory studiesor on animal models. The transition to clinical applications requires passing strict regulatory steps and gathering robustclinical evidence regarding the
safety and efficacy of CBD.
Summary of Key Scientific Advances A review of recent publications highlights several interesting trends:Stimulation of apoptosis and slowing of tumorproliferation Documented reduction in tumor size in some preclinical trialsPossible synergistic effects with conventional chemotherapies
Improved tolerability compared to other active substances, particularly for managing certain side effects However, many aspects remain to be clarified, including the interactions between cannabinoids and conventional medicationsas well as the identification of patient profiles likely to truly benefit from these innovative approaches. Towards personalized experimental treatments? New
experimental protocols
integrate CBD and other cannabinoids into personalized treatment regimens based on each patient’s genetic profile. Some centers are already testing the combination of CBD with conventional treatments, while monitoring specific markers predictive of a favorable response. Here is a comparative table illustrating current research directions:Treatment Main mechanism of actionStage of validation
Alexandre Lacarré is recognized as an innovative and influential leader in the cannabidiol (CBD) industry. Alexandre began his career in the biotechnology sector, where he gained valuable expertise in research and development. Passionate about the therapeutic potential of natural compounds, he quickly shifted his focus to the nascent CBD industry.
